Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Sells Protein Array Business to Aushon

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has sold its SearchLight Protein Array business and technology assets to Aushon BioSystems for an undisclosed amount.

Billerica, Mass.-based Aushon will integrate the SearchLight business but will continue to offer products under the SearchLight brand, it said today.

Aushon, which sells microarray instruments and related consumables for genomic and proteomic applications, gains several products and service capabilities through the deal. Among SearchLight's products are custom protein arrays, chemiluminescent and infrared assay kits, and a CCD imaging and analysis system for immunoassays. SearchLight also offers a custom service that allows researchers to submit samples for quantitative analysis using the firm's biomarker arrays.

"With the addition of the SearchLight technology platform and its products and services, we can now offer our clients a virtual one-stop shop for their biomarker research needs — from microarray printing and custom assay development to biomarker testing services in a CLIA-certified laboratory," Peter Honkanen, CEO of Aushon, said in a statement.

Aushon said that it expects the acquisition will enable it to accelerate biomarker research in preclinical and clinical studies for pharmaceutical, biotech, and diagnostic customers.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.